Before Aetna gained national attention with its plan to merge with fellow health insurer Humana, CEO Mark Bertolini has been hard at work trying to disrupt what he sees as a broken healthcare system, according to a strategy+business blog post.
The American Hospital Association, which already has expressed its concerns about the pending merger between Anthem and Cigna, now has done the same for the Aetna-Humana merger.
Aetna's decision to merge with Humana is not only driven by the smaller company's dominance in Medicare Advantage (MA) business, but also its strong understanding of the consumer-driven trend that has come to dominate the health insurance industry, Aetna CEO Mark Bertolini tells Bloomberg.
Medicare will test a program that changes how it pays for hospice treatment, for the first time allowing patients to receive both curative and palliative treatment, the Centers for Medicare & Medicaid Services announced.
Perhaps trying to ease concerns about the company's impending merger with Humana, Aetna CEO Mark Bertolini reiterated the benefits of the deal in an internal memo to his employees.
Even amid his long career in the health insurance industry, Aetna CEO Mark Bertolini says management style has been shaped perhaps the most by the time he spent in the hospital at his son's side and as a patient himself.
Anthem and Cigna "seem to be making progress toward a deal" following the news of Aetna's planned acquisition of fellow health insurer Humana, CNBC 's David Farber reports.
Now that Aetna and Humana became the first two major health insurers to merge, many questions remain about how the two companies will combine their operations and what the deal will mean for the health insurance industry.
The CEOs of the Big Five for-profit health insurance companies all took home at least $10 million in 2014, according to each insurers' annual filings with the Securities and Exchange Commission.
Although Aetna reported increased fourth quarter profits and Humana said its profits were lower than expected, both insurers have favorable outlooks for 2015--largely because of agreements they've reached with hepatitis c drug maker Gilead.